γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma

Exclusion Criteria

• •1. Intolerance or allergy to any ingredient or similar drug in the treatment plan planned for this study;
• •2. Major organ dysfunction:
• •Cardiac function: Left ventricular ejection fraction (LVEF) ≤ 55%, New York Heart Association (NYHA) grade III or IV congestive heart failure, QTc \> 480 msec, other cardiac diseases as determined by the investigator to be unsuitable for inclusion.
• •Liver function: Child-Pugh liver function classification C or above. Pulmonary function: Severe respiratory failure affecting other organs.
• •3. Uncontrolled epilepsy, severe bleeding risk (such as a recent history of cerebral hemorrhage).
• •4. Active and/or uncontrolled infections (such as tuberculosis, sepsis, opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV) infection, Treponema pallidum (TP) infection).
• •5. Severe, uncontrolled systemic autoimmune or inflammatory diseases (such as systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis, Guillain-Barré syndrome (GBS), amyotrophic lateral sclerosis (ALS)).
• •6. Unstable systemic diseases: unstable angina pectoris, cerebrovascular accident or transient ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), grade III or IV cardiac dysfunction, refractory hypertension (refractory hypertension is defined as: after lifestyle improvement and using appropriate doses of ≥ 4 antihypertensive drugs (including diuretics), blood pressure cannot be effectively controlled after treatment for more than 1 month and still not controlled), severe arrhythmia requiring drug treatment, hepatic arrhythmia, liver disease, kidney disease or metabolic disorders.
• •7. Patients with other malignant tumors.
• •8. Major surgeries within 4 weeks before screening that were assessed by the investigator as unsuitable for inclusion.
• •9. Participated in other interventional clinical studies within 30 days before enrollment.